Global Urinary Tract Infection therapeutics Market - Growth, Trends and Forecast 2017 - 2022

  • ID: 4388593
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global Urinary Tract Infection (UTI) drugs market accounted for a market value of USD XX billion in 2015. The market is expected to reach USD XX billion in 2016 and USD XX billion by 2021, growing at a CAGR of xx% during the forecast period till 2021. According to Kidney and Urology Foundation of America, 1 out of 5 American women will develop UTIs during her lifetime. Kidney and Urology Foundation of America reported that there were 1.5 million hospitalizations for Urinary tract infections in America (2002). This high prevalence rate is a strong cause for R&D in the field and hence the market has great potential.

The market is set to boost with the sudden increase in the prevalence rate and the diagnosis for the disease. This has set to motion the opportunities for major players to implement their resources towards research and development of a combination therapy. This will surely increase the market size during the forecasting period. With the launch of new drugs for multiple indications under UTIs, and label expansion for already existing drugs, the market is set to boost further. The generic, low cost competition for some of the drugs is fierce (e.g. ciprofloxacin, the most prescribed fluoroquinolone), and is forecasted to get more competitive and thus can contribute to offsetting of the figures for current market size.

The UTI Drug market have been, thus segmented based on their type, type of indication they cure and geography. The UTI Drugs have been segmented based on their type and include Penicillin & Combinations, Quinolones, Cephalosporin, Aminoglycoside-Antibodies, Sulphonamides, Azoles & Amphotericin B, Tetracycline and Nitrofurans. The Penicillin & Combinations segment majorly includes the market for Amoxicillin and Amoxicillin-Clavulanate Potassium combination. The Quinolones class includes Ciprofloxacin (Cipro), Levofloxacin (Levaquin), Nalidixic Acid and Norfloxacin. The Cephalosporin class includes Ceftriaxone (Rocephin), Cefuroxime, Cefixime and Cephalexin (Keflex). The Aminoglycoside Antibodies class includes Amikacin and Gentamicin. Sulphonamides majorly consist of Sulfamethoxazole + Trimethoprim combination (Bactrim, Septra, others). Tetracyclines include Doxycycline and Nitrofurans include Nitrofurantoin (Macrodantin, Macrobid).

The UTI Drugs can be classified on the basis of the indications. These classifications include drugs that cure Complicated UTI, Recurring Complicated UTI, Uncomplicated UTI, and Neurogenic Bladder Infection.

This report have been geographically segmented into North America, Europe, Asia-Pacific, Middle East & Africa and South America. The North American region have been further segmented into USA, Canada and Mexico. The Europe region have been sub-divided into Germany, France, UK, Spain,

Italy, Scandinavia, Benelux and Rest of Europe. The Asia-Pacific market have been segmented into Japan, China, India, South Korea, Australia & New Zealand and Rest of Asia-Pacific. The Middle East & African market have been subdivided into GCC countries, South Africa and rest of Middle East and Africa. The South American market have been segmented into Brazil, Argentina and rest of South America. North America accounts for the largest market share.

The current market lacks curative therapy and hence bringing innovative products and tapping the emerging economy will be a great opportunity for the market. The key players in the market are Pfizer, Boehringer Ingelheim, Bayer, GlaxoSmithKline, Novartis, Hoffman-La Roche, Johnson & Johnson, AstraZeneca, Cipla, Cubist Pharma, Osel Inc, Novexel and MerLion Pharmaceuticals.

Key Deliverables:

Market analysis for the UTI Drugs market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on regional scale

Extensively researched competitive landscape section with profiles of major companies along with their market shares

Identification and analysis of the macro and micro factors that affect the Global UTI Drugs market

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
Note: Product cover images may vary from those shown
2 of 3
1.1 Study deliveratives
1.2 Market Definition
1.3 Review and forecast period years
1.4 General Study Assumptions
1.5 Report Description
2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
5.1 Current market scenario
5.2 Porters Five Force Analysis
5.2.1 Bargaining Power of suppliers
5.2.2 Bargaining power of buyers
5.2.3 Degree of competition
5.2.4 Threat of substitution
5.2.5 Threat of new entrants
6.1 Market Drivers
6.1.1 High Prevalence of Related Diseases and improved diagnosis
6.1.2 Launch of Combination Drugs
6.1.3 Expending indications for drugs already in market
6.2 Market Restraints
6.2.1 Intense competition shown by low cost generics
6.3 Market opportunities
6.4 Key Challenges
7.1.1 Penicillin & Combinations Amoxicillin Amoxicillin & Clavulanate Potassium Others
7.1.2 Quinolones Ciprofloxacin (Cipro) Levofloxacin (Levaquin) Nalidixic acid Norfloxacin Others
7.1.3 Cephalosporin Ceftriaxone (Rocephin) Cefuroxime Cefixime Cephalexin (Keflex) Others
7.1.4 Aminoglycoside antibodies Amikacin Gentamicin Others
7.1.5 Sulphonamides Sulfamethoxazole + Trimethoprim (Bactrim, Septra, others) Others
7.1.6 Azoles & Amphotericin B
7.1.7 Tetracycline Doxycycline (Monodox, Vibramycin, others) Others
7.1.8 Nitrofurans Nitrofurantoin (Macrodantin, Macrobid) Others
7.1.9 Others
7.2 Based on Indication
7.2.1 Complicated UTI
7.2.2 Recurring Complicated UTI
7.2.3 Uncomplicated UTI
7.2.4 Neurogenic Bladder Infection
8. Global UTI Drugs market by Geography - Regional shares and forecast
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East and Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of Middle East and Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Pfizer
10.2 Boehringer Ingelheim
10.3 Bayer
10.4 GlaxoSmithKline
10.5 Novartis
10.6 Hoffman-La Roche
10.7 Johnson & Johnson
10.8 AstraZeneca
10.9 Cipla
10.10 Cubist Pharmaceuticals
10.11 Osel Inc
10.12 Novexel
10.13 MerLion Pharmaceuticals
10.14 Others
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown